Science News
from research organizations

New Alzheimer's Treatment Completes First Phase Of Testing

Date:
January 28, 2008
Source:
Purdue University
Summary:
A molecule designed by a Purdue University researcher to stop the debilitating symptoms of Alzheimer's disease has been shown in its first phase of clinical trials to be safe and to reduce biomarkers for the disease. CoMentis, the pharmaceutical company developing the drug, announced completion of its Phase 1 study of a treatment based on the molecule. Results from the study indicate that the treatment is safe and well tolerated.
Share:
       
FULL STORY

Arun Ghosh, at right, a Purdue professor of chemistry and medicinal chemistry, and graduate student Xiaoming Xu discuss the structure of an enzyme inhibitor designed to treat Alzheimer's disease.
Credit: Purdue News Service file photo/David Umberger

A molecule designed by a Purdue University researcher to stop the debilitating symptoms of Alzheimer's disease has been shown in its first phase of clinical trials to be safe and to reduce biomarkers for the disease.

CoMentis, the pharmaceutical company developing the drug, announced on Jan. 7 completion of its Phase 1 study of a treatment based on the molecule. Results from the study indicate that the treatment is safe and well tolerated.

Arun Ghosh, a Purdue professor with a dual appointment in the departments of chemistry and medicinal chemistry and molecular pharmacology, designed the molecule that could allow for intervention in the disease's early stages.

The molecule, called a beta-secretase inhibitor, prevents the first step in a chain of events that leads to amyloid plaque formation in the brain. This plaque formation creates fibrous clumps of toxic proteins that are believed to cause the devastating symptoms of Alzheimer's.

The study of 48 healthy volunteers showed dose-related reduction in plasma amyloid beta, a protein believed to be a key biomarker of Alzheimer's. Results showed a single dose of the drug produced a greater than 60 percent reduction of the biomarker. Subjects received one of six different doses or a placebo, and the study measured levels of the therapeutic drug and levels of the biomarker in the bloodstream.

CoMentis plans to begin a phase II clinical study of the drug, oral CTS-21166, in Alzheimer's patients in 2008.

Alzheimer's disease usually begins after age 60, and the risk increases with age. According to the National Institute on Aging, about 5 percent of men and women ages 65-74 have Alzheimer's disease, and nearly half of those 85 and older may have the disease, for which there is currently no effective treatment.

There is no conclusive test for Alzheimer's. Doctors are able to diagnose "probable Alzheimer's" through a combination of medical tests that include blood tests and brain scans and evaluations of brain function.

"The phase I clinical results are very exciting," Ghosh said. "We hope that this beta-secretase inhibitor drug will be one of the first disease modifying treatments that stops or reverses the symptoms of Alzheimer's disease."


Story Source:

The above post is reprinted from materials provided by Purdue University. Note: Materials may be edited for content and length.


Cite This Page:

Purdue University. "New Alzheimer's Treatment Completes First Phase Of Testing." ScienceDaily. ScienceDaily, 28 January 2008. <www.sciencedaily.com/releases/2008/01/080123101629.htm>.
Purdue University. (2008, January 28). New Alzheimer's Treatment Completes First Phase Of Testing. ScienceDaily. Retrieved July 29, 2015 from www.sciencedaily.com/releases/2008/01/080123101629.htm
Purdue University. "New Alzheimer's Treatment Completes First Phase Of Testing." ScienceDaily. www.sciencedaily.com/releases/2008/01/080123101629.htm (accessed July 29, 2015).

Share This Page: